CO2024003018A2 - Derivados de nucleósido y profármacos de los mismos que tienen acción inhibidora del crecimiento viral - Google Patents

Derivados de nucleósido y profármacos de los mismos que tienen acción inhibidora del crecimiento viral

Info

Publication number
CO2024003018A2
CO2024003018A2 CONC2024/0003018A CO2024003018A CO2024003018A2 CO 2024003018 A2 CO2024003018 A2 CO 2024003018A2 CO 2024003018 A CO2024003018 A CO 2024003018A CO 2024003018 A2 CO2024003018 A2 CO 2024003018A2
Authority
CO
Colombia
Prior art keywords
prodrugs
inhibitory action
growth inhibitory
viral growth
nucleoside derivatives
Prior art date
Application number
CONC2024/0003018A
Other languages
English (en)
Spanish (es)
Inventor
Issei Kato
Masato Kaneda
Masayoshi Miyagawa
Ryota Yamamoto
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of CO2024003018A2 publication Critical patent/CO2024003018A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CONC2024/0003018A 2021-08-20 2024-03-13 Derivados de nucleósido y profármacos de los mismos que tienen acción inhibidora del crecimiento viral CO2024003018A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021134801 2021-08-20
PCT/JP2022/031308 WO2023022216A1 (ja) 2021-08-20 2022-08-19 ウイルス増殖抑制作用を有するヌクレオシド誘導体及びそれらのプロドラッグ

Publications (1)

Publication Number Publication Date
CO2024003018A2 true CO2024003018A2 (es) 2024-03-18

Family

ID=85240607

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0003018A CO2024003018A2 (es) 2021-08-20 2024-03-13 Derivados de nucleósido y profármacos de los mismos que tienen acción inhibidora del crecimiento viral

Country Status (13)

Country Link
US (1) US20250170155A1 (cg-RX-API-DMAC7.html)
EP (1) EP4389750A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2023022216A1 (cg-RX-API-DMAC7.html)
KR (1) KR20240050362A (cg-RX-API-DMAC7.html)
CN (1) CN118119624A (cg-RX-API-DMAC7.html)
AU (1) AU2022331233A1 (cg-RX-API-DMAC7.html)
CA (1) CA3229752A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024003018A2 (cg-RX-API-DMAC7.html)
IL (1) IL310854A (cg-RX-API-DMAC7.html)
MX (1) MX2024002116A (cg-RX-API-DMAC7.html)
PE (1) PE20240654A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023022216A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202401270B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7559223B2 (ja) 2020-08-24 2024-10-01 ギリアード サイエンシーズ, インコーポレイテッド リン脂質化合物及びその使用
US11926645B2 (en) 2020-08-27 2024-03-12 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
TWI925033B (zh) 2020-10-16 2026-05-11 美商基利科學股份有限公司 磷脂化合物及其用途
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
EP4547665A1 (en) 2022-06-30 2025-05-07 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
WO2026160341A1 (ja) * 2025-01-21 2026-07-30 塩野義製薬株式会社 ウイルス感染治療用アザ糖誘導体

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0071227B1 (en) 1981-07-31 1987-11-11 Sloan-Kettering Institute For Cancer Research Anti-leukemic beta-glycosyl c-nucleosides
US5985848A (en) 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
WO2002018371A1 (en) 2000-08-29 2002-03-07 Industrial Research Limited Nucleoside metabolism inhibitors
US7098334B2 (en) 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
BR0309581A (pt) 2002-05-06 2005-03-29 Genelabs Tech Inc Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
SG182849A1 (en) 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
WO2005123087A2 (en) 2004-06-15 2005-12-29 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
US7560434B2 (en) 2004-06-22 2009-07-14 Biocryst Pharmaceuticals, Inc. AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
AU2005302448B2 (en) 2004-10-29 2012-07-19 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
WO2007069924A1 (en) 2005-12-15 2007-06-21 Industrial Research Limited Deazapurine analogs of 4'-aza-l-nucleosides
NZ598927A (en) 2007-01-12 2013-09-27 Biocryst Pharm Inc Antiviral nucleoside analogs
DK2155758T3 (da) 2007-05-10 2012-11-05 Biocryst Pharm Inc Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
TW201305185A (zh) 2010-09-13 2013-02-01 吉李德科學股份有限公司 用於抗病毒治療之2’-氟取代之碳-核苷類似物
US9290501B2 (en) 2010-11-29 2016-03-22 Albert Einstein College Of Medicine, Inc. Methods, assays and compounds for treating bacterial infections by inhibiting methylthioinosine phosphorylase
NZ629996A (en) * 2012-03-13 2016-10-28 Gilead Sciences Inc 2’- substituted carba-nucleoside analogs for antiviral treatment
AR090699A1 (es) 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
MX2015005949A (es) * 2012-11-16 2015-09-08 Biocryst Pharm Inc Nucleosidos que contienen aza-azucar antiviral.
AU2014265483B2 (en) 2013-05-14 2018-08-02 Biocryst Pharmaceuticals, Inc. Anti-influenza compositions and methods
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
TWI698444B (zh) 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
CA2966033A1 (en) 2014-10-31 2016-05-06 Cocrystal Pharma, Inc. 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
JPWO2018199048A1 (ja) 2017-04-25 2020-05-07 大原薬品工業株式会社 ヌクレオシド系抗がん剤または抗ウィルス剤の5’位モノ燐酸ジベンジルエステル誘導体
WO2018230479A1 (ja) 2017-06-13 2018-12-20 大原薬品工業株式会社 ヌクレオシド系抗がん剤又は抗ウィルス剤の5'位シリルエーテル誘導体
WO2019053696A1 (en) * 2017-09-18 2019-03-21 Alios Biopharma, Inc. SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
EP3737359A4 (en) 2018-01-12 2021-11-03 Board of Regents of the University of Nebraska ANTIVIRAL PRODRUGS AND THEIR FORMULATIONS
WO2021040356A1 (en) 2019-08-23 2021-03-04 Kainos Medicine, Inc. C-nucleosides, c-nucleotides and their analogs, equivalents and prodrugs thereof for ectonucleotidase inhibition
CN112778310B (zh) 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN112062800B (zh) 2020-09-02 2022-11-18 广东东阳光药业有限公司 核苷化合物的氨基磷酸酯衍生物及其用途
CN112010916B (zh) 2020-09-09 2022-12-27 广东东阳光药业有限公司 核苷化合物的氨基磷酸酯衍生物及其用途

Also Published As

Publication number Publication date
ZA202401270B (en) 2026-05-27
MX2024002116A (es) 2024-03-06
EP4389750A1 (en) 2024-06-26
PE20240654A1 (es) 2024-04-04
AU2022331233A1 (en) 2024-02-29
JPWO2023022216A1 (cg-RX-API-DMAC7.html) 2023-02-23
CA3229752A1 (en) 2023-02-23
KR20240050362A (ko) 2024-04-18
IL310854A (en) 2024-04-01
WO2023022216A1 (ja) 2023-02-23
US20250170155A1 (en) 2025-05-29
EP4389750A4 (en) 2025-10-01
CN118119624A (zh) 2024-05-31

Similar Documents

Publication Publication Date Title
MX2024002116A (es) Derivados de nucleosido y profarmacos de los mismos que tienen accion inhibidora del crecimiento viral.
CL2023003041A1 (es) Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica
MX2024008987A (es) Derivado de heteroaril-pireno sustituido por anillo puenteado, y uso del mismo.
GEP20247607B (en) Nitrile-containing antiviral compounds
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CL2020000487A1 (es) Agentes antivirales contra la hepatitis b.
CL2020000086A1 (es) Derivado de anillo fusionado que tiene una actividad inhibidora de monoacilglicerol aciltransferasa 2 (mgat-2).
CL2019000415A1 (es) Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéuticos de una infección por el virus del vih.
MX2022010040A (es) Compuestos moduladores de gcn2.
CO2019005534A2 (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
MX2020004838A (es) Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb).
UY38559A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
MX367058B (es) Derivados de nucleosidos sustituidos en 4' como inhibidores de la transcriptasa inversa del virus de inmunodeficiencia adquirida.
CL2020001875A1 (es) Inhibidores de pi4kiiiß
CR20120503A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
ECSP109919A (es) Compuesto de piridacina cristalina
MX387359B (es) Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos.
GEAP202014873A (en) Methods for treatment and prophylaxis of hiv and aids
ECSP20056232A (es) Régimen posológico del modulador del ensamblaje de la cápside
CL2020003380A1 (es) Compuestos que aumentan la actividad del proteosoma.
MX2022004144A (es) Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3.
JOP20200326A1 (ar) مشتقات تترا هيدرو ثينوبيريدين بها استبدال بـ n واستخداماتها
MX2021009261A (es) Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1.
AR099428A1 (es) Combinaciones de principios activos farmacéuticos con compuestos basados en tri(hetero)aril pirazoles
ECSP21078893A (es) Nuevas fenil y piridil ureas activas contra el virus de la hepatitis b (vhb)